Alkermes plc. ($ALKS)
Filing Information
| Accession Number | 0001520262-26-000004 |
|---|---|
| Form Type | 4 |
| Filing Date | Jan 8, 2026 |
| Document Date | Jan 8, 2026 |
| Document | View SEC Filing |
Transactions
3
Total Shares
15,000
Total Value
$246,705.00
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Jan 8, 2026 | Exercise/Conversion | 5,000 | $19.34 | $96,700.00 | 66,740 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Jan 8, 2026 | Sale | 5,000 | $30.00 | $150,005.00 | 61,740 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy) | Derivative | Jan 8, 2026 | Exercise/Conversion | 5,000 | $0.00 | $0.00 | 31,356 | Direct | โ | View Details |